http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
PureTech Year End Update and Outlook for 2024
-
PureTech Health (PRTC) Founded Entity Karuna Therapeutics (KRTX) Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
-
PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
-
PureTech Health (PRTC) Reports Karuna's (KRTX) Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
-
PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
-
PureTech to Present at Two Upcoming Investor Conferences
-
KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia
-
PureTech Health plc – Half-Year Report
-
PureTech Announces Annual Results for Year Ended December 31, 2022
-
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
-
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
-
PureTech Provides End of Year Report on Key Progress
-
PureTech Health plc – Half-Year Report
-
Zai Lab Limited (ZLAB) Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
-
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
-
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
-
PureTech Founded Entity Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I
-
PureTech Founded Entity Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China
-
Karuna Therapeutics Inc. (KRTX) and Zai Lab (ZLAB) Announces Collaboration for Development, Manufacturing, and Commercialization of KarXT in China
-
Zai Lab and Karuna Therapeutics Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China
-
Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China
-
PureTech Health plc – Half-Year Report
-
PureTech Founded Entity Gelesis, the Maker of Plenity®, to Become a Publicly Traded Company via Merger with Capstar Special Purpose Acquisition Corp.
-
PureTech Founded Entity Karuna Therapeutics Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy Elderly Volunteers
-
PureTech Founded Entity Karuna Therapeutics Announces New England Journal of Medicine Publication of Data from EMERGENT-1 Phase 2 Trial Evaluating KarXT in Schizophrenia
-
PureTech Health (PRTC) Receives Approximately $118 Million from Sale of Portion of Founded Entity Shares
-
PureTech Receives Approximately $118 Million from Sale of Portion of Founded Entity Shares
-
PureTech Adds Bharatt Chowrira, PureTech’s President and Chief of Business and Strategy, to Board of Directors
